other material
confidence high
sentiment negative
materiality 0.85
Quince Therapeutics Phase 3 NEAT trial misses primary endpoint; eDSP development halted
Quince Therapeutics, Inc.
- Primary endpoint RmICARS p=0.0851; mean change from baseline -1.30 vs placebo.
- Key secondary endpoint CGI-S also missed (p=0.522).
- eDSP well tolerated; most common adverse events pruritis and pyrexia.
- Company to cease clinical development of eDSP and explore available options.
- Phase 3 NEAT trial enrolled 105 patients with Ataxia-Telangiectasia.